Analysts await Applied Genetic Technologies Corporation (NASDAQ:AGTC) to report earnings on May, 09 for the fiscal quarter ending Mar 2016.

They expect $0.04 EPS, up 1050% or $0.42 from last year’s $-0.38 per share.

At the moment 8 analysts are watching Applied Genetic Technologies Corporation (NASDAQ:AGTC), 4 rate it “Buy”, 4 “Outperform”, 0 “Underperform”, 0 “Sell”, while 0 “Hold”.

Looking forward, for the quarter ending Dec-16, 3 analysts have a mean sales target of 9.88 million. For the quarter ending Mar-16, 7 analysts have a mean sales target of 12.98 million whilst for the year ending Jun-16, 8 analysts have a mean target of 52.31 million.

In terms of earnings per share, 3 analysts have a -0.30 EPS mean target for the quarter ending Dec-16, for the quarter ending Mar-16, 7 analysts have a 0.05 EPS mean target and for the quarter ending Mar-16 there are 8 estimates of -0.10 EPS.

The biggest institutional shareholders in Applied Genetic Technologies Corporation include Fidelity Management and Research Company which owns 2 million shares in the company valued at $35.87 million. InterWest Partners is the second biggest holder with 1 million shares currently valued at 29.87 million whilst Biogen Idec Inc has 1 million shares valued at 26.84 million.

Total shares held by institutions as of the most recent company filings are 17,399,181 with a reported 1,912,767 bought and 3,899,776 sold. These holdings make up 96.64% of the company’s outstanding shares.

Currently insiders hold 24,905 shares in the business which makes up 0.14% of shares. The biggest holder currently is Ms. Susan B. Washer who owns 15,000 shares (0.08% of those outstanding), whilst Dr. Jeffrey D. Chulay holds 7,277 (0.04% of shares outstanding) and Dr. Scott Koenig holds 2,228 (0.01% of shares outstanding).

The stock decreased 1.11% or $0.16 during the last trading session.